The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).
The 21st Century Cures Act, in many ways, helps drugs in other disease areas going through review with FDA get to the same standard of the oncology area, said Mark Fleury, PhD, MS, principal of Policy Development and Emerging Science at the American Cancer Society Cancer Action Network (ACS CAN).
Transcript
How do you think the provisions within the 21st Century Cures Act would impact cancer care in the United States?
The 21st Century Cures Act really was about trying to ensure FDA used its maximum flexibility and was really forward leaning in terms of how they handled drug development. FDA is a large organization and drug review is done by disease type. The oncology review divisions have traditionally been very forward leaning in terms of accepting novel endpoints, novel trial designs, smaller trials, and using more of the accelerated pathways. So, in many ways, 21st Century Cures, from a messaging standpoint, was telling FDA to sort of behave in that aggressive way across disease types. So, it was really an affirmation of the way the cancer review divisions were already behaving.
But one of the things it also did was formalize the Oncology Center of Excellence, and it was really a recognition that somewhere around 40% of all drugs being developed today are for oncology indications. So, it’s the biggest workload that FDA has, and there’s a recognition that that expertise needs to be shared across different reviews. And, also, the message is that FDA is not there to just simply review applications, but they’re really there to develop and promulgate better regulatory science, to help develop the tools that makes it easier and faster to get drugs to patients.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More